As of May 17, 2024, the Ligand Pharmaceuticals stock's PE ratio is 15.79. This results from the current EPS of $5.45 and stock price of $86.06. The P/E ratio has a decrease of 57% from the past four quarters average of 36.4.
The PE ratio of Ligand Pharmaceuticals has averaged 95.06 over the last ten years. The current PE ratio of 15.79 is 83% below the historical average. Over the past ten years, LGND's PE ratio was at its highest in the Sep 2020 quarter at 794.33, when the stock price was $95.32 and the EPS was $0.12. The lowest value was in the Dec 2019 quarter, when it reached 3.15 with a price of $104.29 and an EPS of $33.13.
Maximum annual decrease: -91.22% in 2018
Year | PE ratio | Change |
---|---|---|
2023 | 23.65 | N/A |
2022 | N/A | N/A |
2021 | 44.9 | N/A |
2020 | N/A | N/A |
2019 | 3.15 | -84.28% |
2018 | 20.04 | -91.22% |
2017 | 228.22 | N/A |
2016 | N/A | N/A |
2015 | 9.34 | -89.64% |
2014 | 90.19 | -3.98% |
The current PE ratio of LGND is below the 3, 5 and 10-year averages.
LGND's PE ratio is lower than its peer stocks LLY and MRK, but it is greater than JNJ's and BAX's.
Stock name | PE ratio | Market cap |
---|---|---|
BAX Baxter International Inc | 6.74 | $17.96B |
JNJ Johnson & Johnson | 10.13 | $372.17B |
LGND Ligand Pharmaceuticals Inc | 15.79 | $1.55B |
AMGN Amgen Inc | 44.38 | $167.62B |
LLY ELI LILLY & Co | 112.9 | $731.81B |
MRK Merck & Co Inc | 144.16 | $332.28B |
BMY Bristol Myers Squibb Co | N/A | $89.25B |
PFE Pfizer Inc | N/A | $162.29B |
The price to earnings ratio for LGND stock is 15.79 as of May 17, 2024.
The 3-year average PE ratio for LGND stock is 44.65.
The 5-year average PE ratio for LGND stock is 90.66.
The highest quarterly PE ratio in the last ten years has been 794.33 and it was in the Sep 2020 quarter.
LGND's price to earnings ratio is currently 83% below its 10-year historical average.
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (May 17, 2024), Ligand Pharmaceuticals's stock price is $86.06. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $5.45. Therefore, Ligand Pharmaceuticals's P/E ratio for today is 15.79. PE RATIO(15.79) = STOCK PRICE($86.06) / TTM EPS($5.45)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.